Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F List

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
The Oncologist|November 9, 2001
Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignanciesA F List
Seminars in Oncology|May 29, 1999
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemiaA F List
Leukemia|April 1, 1996
The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemiaA F List
Current Opinion in Oncology|January 1, 1995
Preclinical investigations of drug resistanceA F List
Seminars in Hematology|December 31, 1997
Non-P-glycoprotein drug export mechanisms of multidrug resistanceA F List
Forum (Genoa, Italy)|April 2, 1999
Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromesA F List
The New England Journal of Medicine|February 25, 1988
Metastatic giant-cell bone tumor in a man positive for HIVA F List
Leukemia Research|September 12, 1998
Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?A F List
Leukemia|June 1, 1996
Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemiaA F List
Oncology (Williston Park, N.Y.)|October 1, 1993
Multidrug resistance: clinical relevance in acute leukemiaA F List
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
The Oncologist|November 9, 2001
Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignanciesA F List
Seminars in Oncology|May 29, 1999
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemiaA F List
Leukemia|April 1, 1996
The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemiaA F List
Current Opinion in Oncology|January 1, 1995
Preclinical investigations of drug resistanceA F List
Seminars in Hematology|December 31, 1997
Non-P-glycoprotein drug export mechanisms of multidrug resistanceA F List
Forum (Genoa, Italy)|April 2, 1999
Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromesA F List
The New England Journal of Medicine|February 25, 1988
Metastatic giant-cell bone tumor in a man positive for HIVA F List
Leukemia Research|September 12, 1998
Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?A F List
Leukemia|June 1, 1996
Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemiaA F List
Oncology (Williston Park, N.Y.)|October 1, 1993
Multidrug resistance: clinical relevance in acute leukemiaA F List
Pageof 10